Who
Richard M. Glickman
Director
Company insider
Files Form 4 as: Director, enGene Therapeutics; Director, ESSA Pharma.
In numbers
- Trades disclosed
- 22
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 4 Dec 2013
- Last trade
- 16 Jun 2026
- Last filed
- 17 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jun 2026filed 17 Jun 2026 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,000 at $0.00 | filing |
| 16 Jun 2026filed 17 Jun 2026 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,000 at $0.00 | filing |
| 9 Oct 2025filed 15 Oct 2025 | ESSA Pharma | SEC FORM 4 Code D | —43,240 | filing |
| 16 Jun 2025filed 16 Jun 2025 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 15 Jun 2024filed 18 Jun 2024 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 28 May 2024filed 29 May 2024 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —120 at $0.00 | filing |
| 28 May 2024filed 29 May 2024 | ENGN enGene TherapeuticsBiotechnology | SEC FORM 4 Code M | $107120 at $0.89 | filing |
| 24 Apr 2024filed 25 Apr 2024 | ESSA Pharmaoption or derivative | SEC FORM 4 Code M | —3,750 at $0.00 | filing |
| 24 Apr 2024filed 25 Apr 2024 | ESSA Pharma | SEC FORM 4 Code M | $18K3,750 at $4.90 | filing |
| 25 Mar 2024filed 28 Mar 2024 | ESSA Pharmaoption or derivative | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 31 Oct 2023filed 2 Nov 2023 | ENGN enGene TherapeuticsBiotechnology | SEC FORM 4 Code A | —24,555 | filing |
| 29 Jun 2022filed 1 Nov 2022 | ESSA Pharmaoption or derivative | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 20 Aug 2021filed 2 Nov 2023 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,205 | filing |
| 20 Aug 2021filed 2 Nov 2023 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,001 | filing |
| 14 Dec 2020filed 2 Nov 2023 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,032 | filing |
| 11 Dec 2020filed 26 Jan 2021 | ESSA Pharmaoption or derivative | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 11 Dec 2020filed 11 Jan 2021 | ESSA Pharmaoption or derivative | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 16 Mar 2018filed 2 Nov 2023 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,123 | filing |
| 15 Jun 2017filed 2 Nov 2023 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,188 | filing |
| 11 Jan 2016filed 2 Nov 2023 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,023 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.